Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials
Cancer Innovation · 2026-06 · 5 (3)
DOI: 10.1002/cai2.70065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Innovation, online erschienen am 07.06.2026. Verfasst von Yiyang Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: national natural Science Foundation of China.
Abstract (Originalsprache)
Gynecologic cancers remain a major global health burden for women. Their management has evolved toward a gynecologic oncologist‐led multimodal paradigm. While these approaches have improved outcomes, critical limitations persist, including challenges in decision‐making during surgical procedures and suboptimal efficacy coupled with frequent resistance and substantial toxicities during medical management. Recent high‐quality clinical trials have helped refine these areas. In early‐stage cervical cancer, sentinel lymph node biopsy has emerged as a safe and effective alternative to systematic lymphadenectomy, preserving oncologic outcomes while minimizing morbidity. In advanced ovarian cancer, primary debulking surgery has been established as superior to neoadjuvant chemotherapy followed by interval debulking surgery in fit patients treated at experienced centers. Meanwhile, immunotherapy demonstrates promise through strategic combinations, including dual checkpoint inhibition and triplet regimens incorporating chemotherapy and anti‐angiogenic agents. Antibody‐drug conjugates (ADCs) directed against folate receptor alpha (FRα) and tissue factor (TF) have shown durable responses in biomarker‐selected populations. By critically synthesizing these advances, this review seeks to delineate the clinical utility of emerging therapies, highlight knowledge gaps, and inform evidence‐based decision‐making for clinicians and researchers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
- National Clinical Research Center for Obstetrics and Gynecology, Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji M…
- Division of Oncological Sciences Knight Cancer Institute Oregon Health and Science University Portland Oregon USA.
ORCID-Profile: Qinglei Gao
Förderung
- national natural Science Foundation of China
Zitieren
APA
Shen, Y., Jiao, X., Wen, Y., Peng, Z., Zhao, X., Liu, J., & Gao, Q. (2026). Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials. Cancer Innovation, 5(3). https://doi.org/10.1002/cai2.70065
Vancouver
Shen Y, Jiao X, Wen Y, Peng Z, Zhao X, Liu J, et al. Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials. Cancer Innovation. 2026;5(3). doi:10.1002/cai2.70065
BibTeX
@article{Shen2026,
author = {Shen, Yiyang and Jiao, Xiaofei and Wen, Yuanjia and Peng, Zikun and Zhao, Xuejiao and Liu, Jiahao and Gao, Qinglei},
title = {Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials},
journal = {Cancer Innovation},
year = {2026},
volume = {5},
number = {3},
doi = {10.1002/cai2.70065}
}
EUVIMED